

I hereby certify that this paper (along with any paper referred to as being attached below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: January 5, 2007

Signature:

Shawn P. Foley
(Shawn P. Foley)

Docket No.:
FELDER 3.9-001 CONT DIV
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Felder et al.

Application No.: 10/677,983

Group Art Unit: 1632

Filed: October 2, 2003

Examiner: A. M. Falk

For: G PROTEIN-RELATED KINASE MUTANTS
IN ESSENTIAL HYPERTENSION

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. A copy of each reference was of record in Application No. 09/614,748, which was issued as U.S. patent 6,660,474, the benefit of which is claimed under §120. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.


In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account No. 12-1095.

Dated: January 5, 2007

Respectfully submitted,

By *Shawn P. Foley*
Shawn P. Foley
Registration No.: 33,071
LERNER, DAVID, LITTENBERG,
KRUMHOLZ & MENTLIK, LLP
600 South Avenue West
Westfield, New Jersey 07090
(908) 654-5000
Attorney for Applicant

LD-459\



Under Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/677,983-Conf. #9056
				Filing Date	October 2, 2003
				First Named Inventor	Robin A. Felder
				Art Unit	1632
				Examiner Name	A. M. Falk
Sheet	1	of	2	Attorney Docket Number	FELDER 3.9-001 CONT DIV


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Elseth et al. Principles of Modern Genetics pp. 542-545 1994.	
	CB	Casari et al. Hypertension 25(3):320-326 (1995).	
	CC	Virlon et al. Endocrinology 139(5):2784-2795 (1998).	
	CD	Courjault-Gautier et al., J. Am. Soc. Nephrol. 5:1949-1963 (1994).	
	CE	Detrisac, et al., Kidney Int. 25:383-390 (1984).	
	CF	Jose et al., Pharmacol Ther 80:149-182 (1998).	
	CG	Ng et al., Eur. J. Pharmacol. 267:7-19 (1994).	
	CH	Premont, et al., FASEB J. 9:175-182 (1995).	
	CI	Palczewski, Protein Sci. 3:1355-1361 (1994).	
	CJ	Inglese, et al., J. Biol. Chem. 268:23735-23738 (1993).	
	CK	Gros, J. Clin. Invest. 99(9):2087-2093 (1997).	
	CL	Ambrose, et al., Hum. Mol. Genet. 1:697-703 (1993).	
	CM	Sallese et al., Biochem. Biophys. Res. Commun. 199:848-854 (1994).	
	CN	Menard, et al., Biochemistry 35(13):4155-4160 (1996).	
	CO	Loudon, et al., J. Biol. Chem. 272(43):27422-27427 (1997).	
	CP	Premont, et al., J. Biol. Chem. 271(11):6403-6410 (1996).	
	CQ	Albrecht, et al., J. Clin. Invest. 97(10):2283-2288 (1996).	
	CR	Ohbu, et al., American J. of Physiology 268:R231-R235 (1995).	
	CS	Eisner, et al., Am. J. Physiol. 273:R317-R323 (1997).	
	CT	Jin, et al., Am. J. Physiol. 273:C1623-C1631 (1997).	
	CU	Woost, et al., Kidney International 50:125-134 (1996).	
	CV	Chen, et al., Kidney International 49:153-157 (1996).	
	CW	Racusen, et al., Kidney International 48:536-543 (1995).	
	CX	Ryan, et al., Kidney International 45:48-57 (1994).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/677,983-Conf. #9056
				Filing Date	October 2, 2003
				First Named Inventor	Robin A. Felder
				Art Unit	1632
				Examiner Name	A. M. Falk
				Attorney Docket Number	FELDER 3.9-001 CONT DIV
Sheet	2	of	2		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--